A Novel Heart Failure Diagnostic Risk Score Using a Minimally Invasive Subcutaneous Insertable Cardiac Monitor
Authors' conclusion
ICM-HFRS provides a multiparameter, integrated diagnostic method with the ability to identify when HF patients are at increased risk of heart failure events.
Study context
- Population
- Patients with NYHA class II/III heart failure (HF) across the EF spectrum, implanted with a subcutaneous insertable cardiac monitor (ICM)
- Participants
- 42 vs 94
- Comparison
- Development vs Validation
- Developmentn = 42
- Validationn = 94
- Outcome
- ICM-based HF risk score (heart failure risk score (HFRS)) performance to predict HF events (sensitivity, unexplained detection rate)
- Follow-up
- Within 30 days
Methodological details2 observational cohorts, development and validation data sets
- 2 observational cohorts
- Development and validation data sets
Performance
As reported in the abstract
HFRS performance at high-risk threshold 7.5%
| Test or model | Value | Sensitivity | Unexplained detection rate | Median early warning before heart failure event (HFE) |
|---|---|---|---|---|
| Development | 19 events | 73.7% | 1.4 per patient-year | 47 days |
| Validation | 19 events | 68.4% | 1.5 per patient-year | 64 days |
Value
Development19 events
Validation19 events
Sensitivity
Development73.7%
Validation68.4%
Unexplained detection rate
Development1.4 per patient-year
Validation1.5 per patient-year
Median early warning before heart failure event (HFE)
Development47 days
Validation64 days
Original publication
A Novel Heart Failure Diagnostic Risk Score Using a Minimally Invasive Subcutaneous Insertable Cardiac Monitor. JACC Heart Fail. Published 8 November 2023. doi:10.
Summarised from the published abstract; every number is checked against it